Filing Details

Accession Number:
0000939767-17-000025
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-03 20:20:12
Reporting Period:
2017-03-03
Filing Date:
2017-03-03
Accepted Time:
2017-03-03 20:20:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
939767 Exelixis Inc. EXEL Services-Commercial Physical & Biological Research (8731) 043257395
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1648367 J. Christopher Senner C/O Exelixis, Inc.
210 East Grand Ave.
South San Francisco CA 94080
Evp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-03-03 11,000 $22.80 100,398 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,783 Indirect By 401(k)
Footnotes
  1. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.80 to $22.81. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.
  2. Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 5,422 shares of common stock acquired pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. The total number of shares reported has been reduced by 20,000 shares due to prior inadvertent over-reporting of the total number of shares beneficially owned by the Reporting Person.
  3. Represents 1,783 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of March 2, 2017.